Alpine Immune Sciences initiates second dosing cohort in RUBY-3 study

Alpine Immune Sciences announced the successful initiation of the second IgA nephropathy dose cohort in RUBY-3, a phase 1b/2a study in autoimmune glomerulonephritis. Safety Monitoring Committee review has determined that repeat dosing of povetacicept in the first IgAN dose cohort has been safe and well-tolerated to date, with no serious or severe adverse events, no events of hypogammaglobulinemia, and no instances of hypersensitivity or administration-related reactions. Dose escalation has been endorsed, and enrollment of the second IgAN dose cohort has been initiated. “We are encouraged by this first in-disease experience with the lowest dose level of povetacicept in this study, confirming its initial safety and pharmacodynamic activity during multiple dose administration,” noted Stanford Peng, President and Head of Research and Development at Alpine. “We look forward to providing more detailed clinical updates later this year in appropriate scientific forums.”